Trials / Withdrawn
WithdrawnNCT04134468
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors. Subjects will received Gemcitabine, Abraxane and PEGPH20.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegvorhyaluronidase alfa | IV infusion |
| DRUG | Abraxane | IV infusion |
| DRUG | Gemcitabine | IV infusion |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-02-11
- Completion
- 2022-11-11
- First posted
- 2019-10-22
- Last updated
- 2020-01-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04134468. Inclusion in this directory is not an endorsement.